US Oncology Research, The US Oncology Network and McKesson Specialty ... Wall Street Journal (press release) Saturday, June 1, 1:30pm - 1:45pm, E354a Tolerability and activity of combinations of the PI3K inhibitor idelalisib (GS-1101) with rituximab and/or bendamustine in patients with previously treated, indolent non-Hodgkin lymphoma (iNHL): Updated results ... |
